What is Signify Bio?
Founded in 2025, Signify Bio operates at the vanguard of the biotechnology sector, focusing on the development of localized therapeutic proteins. By leveraging the human body's innate capacity for protein synthesis, the company utilizes its proprietary SEND (Signal peptide Engineered Nucleic acid Design) and iPhos lipid nanoparticle technologies to facilitate targeted delivery. This approach represents a paradigm shift in personalized medicine, moving away from systemic administration toward localized, high-precision treatment modalities. Through a strategic partnership with the University of Texas Southwestern Medical Center, Signify Bio is effectively bridging the gap between academic research and commercial-scale nucleic acid engineering, positioning itself as a critical player in the future of genetic disorder management.
How much funding has Signify Bio raised?
Signify Bio has raised a total of $15M across 1 funding round:
Other Financing Round
$15M
Other Financing Round (2025): $15M with participation from BrightEdge, Danaher, Eli Lilly, and Actium Group
Key Investors in Signify Bio
BrightEdge
The innovation and impact investment arm of the American Cancer Society, focusing on scalable solutions to address critical unmet needs in cancer treatment and scientific discovery.
Danaher
A global leader in life sciences and diagnostics, providing integrated bioprocess technologies and advanced analytical instrumentation essential for therapeutic development.
Eli Lilly
A global biopharmaceutical firm dedicated to research-driven innovation in areas including oncology, immunology, and neuroscience.
What's next for Signify Bio?
The recent influx of capital will be instrumental in scaling Signify Bio's operational capabilities and advancing its pipeline through critical preclinical milestones. As the company transitions from its foundational phase into a more robust scaling stage, the focus will likely shift toward optimizing its manufacturing processes and expanding its intellectual property portfolio. By integrating the specialized expertise of its strategic backers, Signify Bio is poised to refine its delivery platforms, potentially setting new benchmarks for efficacy in protein-based therapeutics. Future growth will be defined by the company's ability to translate its innovative engineering designs into viable clinical candidates, thereby addressing significant unmet needs in the global biopharmaceutical landscape.
See full Signify Bio company page
